Landos Biopharma, Inc.
LABP · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,151 | $3,147 | $3,063 | $2,463 |
| G&A Expenses | $6,144 | $3,463 | $2,136 | $1,976 |
| SG&A Expenses | $6,144 | $3,163 | $2,136 | $1,976 |
| Sales & Mktg Exp. | $0 | -$300 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,295 | $6,310 | $5,199 | $4,439 |
| Operating Income | -$9,295 | -$6,310 | -$5,199 | -$4,439 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $398 | $191 | -$661 | $517 |
| Pre-Tax Income | -$8,897 | -$6,119 | -$5,860 | -$3,922 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8,897 | -$6,119 | -$5,860 | -$3,922 |
| % Margin | – | – | – | – |
| EPS | -1.43 | -0.99 | -0.94 | -0.63 |
| % Growth | -44.4% | -5.3% | -49.2% | – |
| EPS Diluted | -1.43 | -0.99 | -0.94 | -0.63 |
| Weighted Avg Shares Out | 6,208 | 6,208 | 6,208 | 6,208 |
| Weighted Avg Shares Out Dil | 6,208 | 6,208 | 6,208 | 6,208 |
| Supplemental Information | – | – | – | – |
| Interest Income | $401 | $0 | $0 | $0 |
| Interest Expense | $0 | $546 | $0 | $557 |
| Depreciation & Amortization | $43 | $12 | -$40 | $40 |
| EBITDA | -$9,252 | -$5,561 | -$5,199 | -$4,399 |
| % Margin | – | – | – | – |